Abstract: Pulmonary arterial hypertension(PAH) is a progressive and fatal disease,characterized by elevated pulmonary vascular resistance and pulmonary arterial pressure,most often resulting in right-sided heart failure.The mechanisms of action,approved PAH therapies and the latest agents in late-stage clinical development were reviewed and described in this paper.